Welcome to our dedicated page for Aethlon Medical SEC filings (Ticker: AEMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Aethlon Medical’s SEC paperwork can feel harder than understanding its Hemopurifier science. Pages of R&D expense tables, FDA correspondence, and dilution math often bury the details investors need. Stock Titan’s AI turns that maze into a clear map.
Search “Aethlon Medical annual report 10-K simplified” or “Aethlon Medical quarterly earnings report 10-Q filing” and arrive here first. Our platform ingests every 8-K, 10-Q, 10-K, S-1, and Aethlon Medical insider trading Form 4 transactions the moment they hit EDGAR. Then AI highlights the burn rate behind Hemopurifier trials, flags new biodefense grants, and explains why an 8-K mentions protocol amendments—so you understand Aethlon Medical 8-K material events explained without legalese.
Need rapid insight? Toggle real-time alerts for Aethlon Medical Form 4 insider transactions real-time to see when executives buy shares during pivotal oncology data releases. Compare segments with our visual summaries inside each “Aethlon Medical earnings report filing analysis”. Drill into the proxy to examine Aethlon Medical proxy statement executive compensation, or ask natural questions like “understanding Aethlon Medical SEC documents with AI” and get concise answers. Whether you track Aethlon Medical executive stock transactions Form 4 before financing rounds or gauge trial milestones hidden in MD&A, our coverage keeps you ahead—no PhD in regulatory jargon required.
Aethlon Medical (Nasdaq:AEMD) filed a Form 8-K to furnish its press release announcing financial results for the quarter ended March 31, 2025. Reported under Items 2.02 and 7.01, the filing attaches the release as Exhibit 99.1 and states the information is provided under Regulation FD and not deemed “filed” for Exchange Act purposes. No detailed financial metrics, guidance, or strategic updates are included in the 8-K itself. Aside from furnishing the exhibit, the report discloses no material events likely to affect the company’s operating outlook or capital structure. Investors must review Exhibit 99.1 for the actual results.
Aethlon Medical (NASDAQ:AEMD) filed its Annual Report for the fiscal year ended March 31, 2025.
- Maintains status as a non-accelerated filer & smaller reporting company.
- Implemented a 1-for-8 reverse stock split effective June 6 2025; post-split shares outstanding total 2,585,316.
- Aggregate market value of non-affiliate shares was $6.65 million as of Sept 30 2024 (close $3.73).
- Discloses May 2024 public offering and March 2025 warrant inducement; details appear in Equity & Liquidity sections.
- No indication of being a shell company or well-known seasoned issuer; all Exchange Act filings current.
The filing provides audited FY 2025 financial statements, updated risk factors, new Cybersecurity disclosures and forward-looking statements that may affect future capital raising and regulatory pathways.
FAQ
What is the current stock price of Aethlon Medical (AEMD)?
What is the market cap of Aethlon Medical (AEMD)?
What is the primary focus of Aethlon Medical?
How does the Hemopurifier® work?
In what clinical settings is the Hemopurifier® being tested?
What regulatory designations has the Hemopurifier® received?
How does Aethlon Medical ensure the safety and efficacy of its device?
What makes Aethlon Medical's approach unique?
Who are the likely beneficiaries of Aethlon Medical's products?
How does the company position itself within the competitive medical device market?
